GoldenGolden
Advanced Search
Edesa Biotech

Edesa Biotech

Edesa Biotech is a Markham, Ontario-based biotechnology company working on non-steroidal topical treatment alternatives for inflammatory and autoimmune diseases. Edesa Biotech is a wholly owned subsidiary of Stellar Biotechnologies.

All edits

Edits on 9 Jun, 2021
Erin Scherfner"prospector:320:158492"
Erin Scherfner edited on 9 Jun, 2021
Edits made to:
Infobox (+2 properties)
Infobox
Country
Canada
Edits on 12 May, 2021
Golden AI"Funding autocalculation"
Golden AI edited on 12 May, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Latest funding type
Edits on 1 Feb, 2021
Golden AI"prospector:137:67696"
Golden AI edited on 1 Feb, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 6 Oct, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 6 Oct, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Latest funding round date
September 20, 2017
Edits on 17 Jul, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 17 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Total funding amount (USD)
7,000,000
Edits on 9 May, 2020
Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 9 May, 2020
Edits made to:
Article (+23/-23 characters)
Article

In May 2019, Stellar BiotechnologiesStellar Biotechnologies shareholders approved a reverse merger with Edesa Biotech, in which the privately owned Edesa Biotech was brought onto the public market under Stellar Biotechnologies shares on the NASDAQ. As per the terms of the agreement, Edesa Biotech shareholders exchanged their shares for newly issued shares of Stellar. Edesa Biotech shareholders would own 90% of the new company. The new company retains Edesa Biotech's name, but the company has become a wholly owned subsidiary of Stellar Biotechnologies.

Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 9 May, 2020
Edits made to:
Article (+6/-6 characters)
Article

In May 2019, Stellar Biotechnologies shareholders approved a reverse merger with Edesa Biotech, in which the privately owned Edesa Biotech was brought onto the public market under Stellar Biotechnologies shares on the NASDAQNASDAQ. As per the terms of the agreement, Edesa Biotech shareholders exchanged their shares for newly issued shares of Stellar. Edesa Biotech shareholders would own 90% of the new company. The new company retains Edesa Biotech's name, but the company has become a wholly owned subsidiary of Stellar Biotechnologies.

Edits on 8 May, 2020
Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 8 May, 2020
Edits made to:
Article (+15/-15 characters)
Article

As of April 2020, Edesa Biotech's clinical pipeline includes their EB01 topical treatment for contact dermatitis which was in Phase 2 of clinical trialsclinical trials; their EB01 topical treatment for hemorrhoids which was in Phase 1 of clinical trials; their EB04 topical treatment for anal fissures which was in Phase 1 of clinical trials; their EB05 and EB06 acute respiratory distress syndrome mAb treatment which were both in Phase 2 of clinical trials; and their immunotherapy for vitiligo which was heading into lead optimization as of April, 2020.

Aleksander Holm
Aleksander Holm edited on 8 May, 2020
Edits made to:
Infobox (+1/-1 properties)
Description (+232 characters)
Article (+1629 characters)
Topic thumbnail

Edesa Biotech

Edesa Biotech is a Markham, Ontario-based biotechnology company working on non-steroidal topical treatment alternatives for inflammatory and autoimmune diseases. Edesa Biotech is a wholly owned subsidiary of Stellar Biotechnologies.

Article

Edesa Biotech is a clinical-stage private company focused on developing treatments for dermatological and anorectal diseases. Their initial focus is on developing novel, safe and potent alternatives to steroids for allergic contact dermatitis, hemorrhoids, and anal fissures. Edesa Biotech's lead asset, EB01 is a novel non-steroidal anti-inflammatory molecule for the treatment of allergic contact dermatitis which has already demonstrated statistically significant improvements in multiple clinical studies.

Clinical Pipeline

As of April 2020, Edesa Biotech's clinical pipeline includes their EB01 topical treatment for contact dermatitis which was in Phase 2 of clinical trials; their EB01 topical treatment for hemorrhoids which was in Phase 1 of clinical trials; their EB04 topical treatment for anal fissures which was in Phase 1 of clinical trials; their EB05 and EB06 acute respiratory distress syndrome mAb treatment which were both in Phase 2 of clinical trials; and their immunotherapy for vitiligo which was heading into lead optimization as of April, 2020.

Stellar Biotechnology Merger

In May 2019, Stellar Biotechnologies shareholders approved a reverse merger with Edesa Biotech, in which the privately owned Edesa Biotech was brought onto the public market under Stellar Biotechnologies shares on the NASDAQ. As per the terms of the agreement, Edesa Biotech shareholders exchanged their shares for newly issued shares of Stellar. Edesa Biotech shareholders would own 90% of the new company. The new company retains Edesa Biotech's name, but the company has become a wholly owned subsidiary of Stellar Biotechnologies.

Infobox
Total funding amount (USD)
7,000,000
Parent organization
Golden AI"Funding autocalculation"
Golden AI edited on 8 May, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Total funding amount (USD)
7,000,000
Golden AI
Golden AI edited on 8 May, 2020
Edits made to:
Infobox (+1 properties)
Golden AI"Location lookup using: 100 Spy Court, Markham, ON L3R 5H6, CA"
Golden AI edited on 8 May, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Location
Aleksander Holm
Aleksander Holm edited on 8 May, 2020
Edits made to:
Infobox (+19 properties)
Table (+5 rows) (+15 cells) (+545 characters)
Topic thumbnail

Edesa Biotech

Edesa Biotech is a Markham, Ontario-based biotechnology company working on non-steroidal topical treatment alternatives for inflammatory and autoimmune diseases. Edesa Biotech is a wholly owned subsidiary of Stellar Biotechnologies.

Table

Name
Role
LinkedIn

Blair Gordon, PhD

Vice President, Research and Development

Gary Koppenjan

Vice President, Investor Relations and Communications

Kathi Niffenegger, CPA

Chief Financial Officer

Par Nijhawan, MD, FRCPC, AGAF

Chief Executive Officer

Infobox
Email address
info@edesabiotech.com
Founded date
2015
Full address
Industry
Investors
Phone number
Stock exchange
Stock symbol
EDSA
Edits on 25 Nov, 2019
Golden AI
Golden AI edited on 25 Nov, 2019
Edits made to:
Infobox (+1 properties)
Edits on 8 Jul, 2019
Golden AI"Remove default description"
Golden AI edited on 8 Jul, 2019
Edits made to:
Description (-7 characters)
Topic thumbnail

Edesa Biotech

Company

Edits on 17 Apr, 2019
Golden AI
Golden AI edited on 17 Apr, 2019
Edits made to:
Description (+7 characters)
Topic thumbnail

Edesa Biotech

Company

Edits on 7 Mar, 2019
Golden AI
Golden AI edited on 7 Mar, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 6 Mar, 2019
Lourdelyn Cagadas
Lourdelyn Cagadas approved a suggestion from Golden's AI on 6 Mar, 2019
Edits made to:
Infobox (+2 properties)
Lourdelyn Cagadas"Initial topic creation"
Lourdelyn Cagadas created this topic on 6 Mar, 2019
Edits made to:
Topic thumbnail

 Edesa Biotech

Edesa Biotech is a Markham, Ontario-based biotechnology company working on non-steroidal topical treatment alternatives for inflammatory and autoimmune diseases. Edesa Biotech is a wholly owned subsidiary of Stellar Biotechnologies.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.